Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.15 | — | — | — | — | — | — | — | 20.40 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | 1233.48 | 11.55 | 7.17 | 12.22 | 7.41 | 4.11 | 3.47 | 3.61 | 5.24 | 7.54 | 2.91 | 3.66 | 2.53 | 1.89 | 2.55 | 2.12 |
| — | — | — | — | — | +16553.8% | +180.8% | +106.4% | +238.4% | +41.2% | -45.4% | +19.5% | -1.3% | +107.6% | +298.2% | +13.8% | +73.0% | -6.1% | -41.5% | -39.7% | -47.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7467.2% | — | — | — | — | -333.5% | -71.6% | -75.5% | -60.6% | -69.7% | -35.2% | -27.3% | -14.0% | -28.9% | -23.1% | -18.2% | -23.0% | -11.4% | -12.1% | -15.1% | -15.6% |
| — | — | — | — | — | -378.3% | -103.7% | -176.8% | -334.2% | -141.5% | -52.3% | -49.8% | +39.2% | -153.2% | -90.4% | -21.0% | -47.1% | -31.6% | +6.3% | -2.8% | +61.8% | |
| ROA | -188.0% | -143.7% | -119.3% | -117.4% | -81.1% | -59.1% | -22.7% | -23.6% | -20.5% | -33.9% | -21.7% | -18.7% | -9.3% | -19.0% | -16.5% | -13.1% | -16.5% | -8.5% | -9.4% | -11.8% | -12.5% |
| — | -143.3% | -425.2% | -397.1% | -295.3% | -74.3% | -4.6% | -26.0% | -120.5% | -78.7% | -31.9% | -43.1% | +43.7% | -122.5% | -74.7% | -10.5% | -32.3% | -20.0% | +11.8% | -3.2% | +56.1% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -51.1% | -29.1% | -80.3% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 7.26 | 0.15 | 0.15 | 0.18 | 0.12 | 0.06 | 0.05 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | — | — | — | — | +6080.6% | +139.3% | +213.8% | +1058.8% | +563.2% | +183.0% | +122.8% | +9.0% | +9.2% | +26.9% | +32.0% | -22.4% | -2.5% | +6.0% | +19.4% | +11.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.12 | 0.89 | 1.35 | 1.38 | 1.12 | 1.84 | 2.88 | 3.21 | 2.82 | 2.99 | 4.99 | 8.14 | 9.01 | 4.53 | 11.69 | 13.88 | 9.05 | 10.42 | 15.49 | 17.96 | 16.69 |
| — | -51.4% | -53.0% | -56.9% | -60.3% | -38.6% | -42.3% | -60.6% | -68.7% | -33.9% | -57.3% | -41.4% | -0.4% | -56.6% | -24.5% | -22.7% | -45.8% | -45.3% | -27.9% | -18.9% | +34.0% | |
| Quick Ratio | 1.12 | 0.89 | 1.35 | 1.38 | 1.12 | 1.84 | 2.88 | 3.21 | 2.82 | 2.99 | 4.99 | 8.14 | 9.01 | 4.53 | 11.69 | 13.88 | 9.05 | 10.42 | 15.49 | 17.96 | 16.69 |
| — | -51.4% | -53.0% | -56.9% | -60.3% | -38.6% | -42.3% | -60.6% | -68.7% | -33.9% | -57.3% | -41.4% | -0.4% | -56.6% | -24.5% | -22.7% | -45.8% | -45.3% | -27.9% | -18.9% | +34.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONCY stock.
Oncolytics Biotech Inc.'s current P/E is -2.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Oncolytics Biotech Inc.'s business trajectory between earnings reports.